Single-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3372689
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 23
- 试验地点
- 1
- 主要终点
- Number of Participants with One or More Serious Adverse Event(s) (SAEs) Observed by the Investigator During Study Drug Administration
研究概览
简要总结
This study is being conducted to determine the safety profile of the study drug after it is given by mouth to healthy participants. Blood tests will be performed to check how much LY3372689 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive up to 3 doses of LY3372689 or placebo. The study will last about 12 weeks, including screening.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Overtly healthy male or a female who cannot get pregnant
- •Have a body mass index (BMI) of at least 18.5 kilogram per square meter (kg/m²), inclusive, at screening
- •Have normal blood pressure, pulse rate, electrocardiogram (ECG, heart tracing), blood and urine laboratory test results that are acceptable for the study
- •Have veins suitable for ease of blood sampling
排除标准
- •Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study
- •Have previously participated or withdrawn from this study
- •Smoke more than the equivalent of 10 cigarettes per day and are unwilling to stop smoking for study procedure
- •Have or used to have health problems or laboratory test results or ECG readings that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
- •Have long exposure to sunlight routinely or use tanning beds regularly
研究组 & 干预措施
LY3372689
Escalating doses of LY3372689 administered orally in healthy participants in two of three study periods
干预措施: LY3372689 (Drug)
Placebo
Matching placebo administered orally in healthy participants in one of three study periods
干预措施: Placebo (Drug)
结局指标
主要结局
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Observed by the Investigator During Study Drug Administration
时间窗: Baseline through final follow-up at approximately Week 12
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
次要结局
- Pharmacokinetics: Time to Maximum Blood Concentration (Tmax) of LY3372689(Baseline through final follow-up at approximately Week 12)
- Pharmacokinetics: Maximum Concentration (Cmax) of LY3372689(Baseline through to final follow-up at approximately Week 12)
- Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY3372689(Baseline through final follow-up at approximately Week 12)